DSXS topical product
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Scalp Psoriasis
Conditions
Scalp Psoriasis
Trial Timeline
Jul 11, 2016 → Jan 2, 2018
NCT ID
NCT02933502About DSXS topical product
DSXS topical product is a phase 2 stage product being developed by Sun Pharmaceutical for Scalp Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT02933502. Target conditions include Scalp Psoriasis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02933502 | Phase 2 | Completed |
| NCT02933528 | Phase 2 | Completed |
Competing Products
7 competing products in Scalp Psoriasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| PART 1: Double-blind Placebo-controlled + PART 2: Double-blind Active Treatment Extension | Sun Pharmaceutical | Phase 3 | 77 |
| DSXS + Placebo | Sun Pharmaceutical | Phase 3 | 77 |
| DSXS topical + Vehicle topical | Sun Pharmaceutical | Phase 3 | 77 |
| Betamethasone Scalp Suspension 0.064%;0.0005% + Taclonex® + Placebo topical suspension | Sun Pharmaceutical | Phase 1 | 33 |
| Calcipotriene/Betamethasone Dipropionate + Taclonex® + Placebo | Glenmark Pharmaceuticals | Phase 3 | 77 |
| Secukinumab 300 mg + Placebo | Novartis | Phase 3 | 77 |
| Roflumilast Foam 0.3% + Vehicle Foam | Arcutis Biotherapeutics | Phase 3 | 72 |
Other Products from Sun Pharmaceutical
Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85